SynthesisJournal of clinical hypertension (Greenwich, Conn.)2013
Renal sympathetic denervation for treatment of resistant hypertension: a systematic review.
Synthesis in Journal of clinical hypertension (Greenwich, Conn.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Renal denervation, adjusted drugs, or combined therapy for resistant hypertension: A meta-regression.Medicine · 2016Pooled it
- Role of peripheral 5-HTScientific reports · 2020Article
- Renal sympathetic denervation for resistant hypertension: where do we stand after more than a decade.Jornal brasileiro de nefrologia · 2020Review
- One year follow-up effect of renal sympathetic denervation in patients with resistant hypertension.ARYA atherosclerosis · 2016Article
- Transcatheter renal interventions: a review of established and emerging procedures.Journal of clinical imaging science · 2015Review
- Meta-methodology: conducting and reporting meta-analyses.Journal of clinical hypertension (Greenwich, Conn.) · 2014Article
- Management of hypertension in the hemodialysis population: a review of the literature.Journal of community hospital internal medicine perspectives · 2014Review
- Renal sympathetic denervation for resistant hypertension treatment : current perspectives.Arquivos brasileiros de cardiologia · 2013Review
- Renal sympathetic denervation in resistant hypertension.World journal of cardiology · 2013Article
- Genetic and Adverse Health Outcome Associations with Treatment Resistant Hypertension in GenHAT.International journal of hypertension · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Catheter-based renal sympathetic denervation (RSD) is a novel technique that is being investigated as treatment for resistant hypertension. To systematically evaluate the existing literature on the safety and efficacy of RSD in persons with resistant hypertension, online searches of Medline and the Cochrane Library Database (up to June 2012) were performed. Randomized controlled trials, observational studies, and conference proceedings published in English language were included. Nineteen studies (N=683 persons) were included. Follow-up duration ranged from 1 to 24 months. All studies reported significant reductions in systolic and diastolic pressures. Maximal reduction of blood pressure ranged from 18 mm Hg to 36 mm Hg (systolic) and 9 mm Hg to 15 mm Hg (diastolic). Sustained benefit of blood pressure reduction at 12 months was seen in 5 studies. No worsening of renal function was reported and there were few procedure-related adverse events such as pseudoaneurysm formation, hypotension, and bradycardia. Data from short-term studies suggest that RSD is a safe and effective therapeutic option in carefully selected patients with resistant hypertension. Long-term studies with large patient populations are needed to study whether this benefit is sustained with a demonstrable difference in cardiovascular disease event rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.